NRX Pharmaceuticals, Inc. — Director's Dealing 2021

Nov 2, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: NRX Pharmaceuticals, Inc. (NRXP)
CIK: 0001719406
Period of Report: 2021-08-16

Reporting Person: Besthof Robert (Chief Comm. & Patient Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-08-16	Common Stock	M	63710	$0.20	Acquired	63710	Direct
2021-09-15	Common Stock	S	40000	$11.76	Disposed	23710	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-08-16	Employee Stock Option (Right to buy)	$0.20	C	100000	Disposed	2026-03-01	Common Stock (100000)	Direct
2021-08-16	Restricted Stock Units	$	A	36290	Acquired		Common Stock (36290)	Direct

Footnotes

F1: The options are fully vested.

F2: Shares and restricted stock units acquired pursuant to the exercise of 100,000 vested stock options under the NRX Pharmaceuticals, Inc. 2021 Omnibus Incentive Plan (the "Plan"). The Reporting person received 63,701 freely tradable shares of common stock, par value $0.001 per share, of NRX Pharmaceuticals, Inc. (the "Common Stock") and 36,290 restricted stock units, each restricted stock unit representing a right to receive one share of Common Stock. The restricted stock units remain in the Plan and are subject to forfeiture if the Earnout Share Milestone and the Earnout Cash Milestone (as defined in the Merger Agreement) do not occur on or prior to December 31, 2022.